Differential effects of different cytokines on the tumorigenicity and immunogenicity of murine tumors

Chinese Medical Journal (Taipei)

Volumn 62, Issue 11, 1999, Pages 807-816

  Chen, Yuh Min ^a   Tsai, Chun Ming ^b   Perng, Reury Perng ^b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NONE

Author keywords

Cytokine; Granulocyte macrophage colony stimulating factor; Inteleukin 10; Interleukin 4; Interleukin 12; Melanoma cell line

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; TUMOR VACCINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE TRANSFER; IMMUNIZATION; IMMUNOGENICITY; LUNG METASTASIS; MOUSE; NONHUMAN; SPLEEN CELL; TUMOR;

ANIMALS; CANCER VACCINES; CYTOKINES; FEMALE; IMMUNIZATION; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SKIN NEOPLASMS;

EID: 0032724664     PISSN: 05781337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
2. Nishimura T, Watanabe K, Yahata T, Ushaku L, Ando K, Kimura M, et al. Application of interleukin 12 to antitumor cytokine and gene therapy. Cancer Chemother Pharmacol 1996;38:s27-34.
3. Abdel-Wahab Z, Dar M, Osanto S, Fong T, Vervaert CE, Hester D, et al. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon. Cancer Gene Therapy 1997;4:33-41.
4. Wang J, Yang WK, Yang Y, Wei SJ, Yang DM, Whang-Peng J, et al. Paradoxical effect of GM-CSF gene transfer on the tumorigenicity and immunogenicity of murine tumors. Int J Cancer 1998;75:459-66.
5. Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci USA 1996;93:7826-31.
6. Yoshizawa H, Chang AE, Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunology 1991;147:729-37.
7. Tamada K, Harada M, Okamoto T, Takenoyama M, Ito O, Matsuzaki G ,et al. Specific antitumor activity of tumorinfiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2. Cancer Immunol Immunother 1995;41:339-47.
8. Chen YM, Yang WK, Whang-Peng J, Kuo BIT, Perng RP. Elevation of interleukin-10 levels in malignant pleural effusion. Chest 1996;110:433-6.
9. Chen YM, Yang WK, Ting CC, Tsai WY, Yang DM, Whang-Peng J, et al. Cross regulation by IL-10 and IL-2/IL-12 of the cytolytic activity of lymphocyte from malignant effusion of lung cancer patients. Chest 1997;112:960-6.
10. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994;84:4008-27.
11. Kennedy MK, Picha KS, Shanebeck KD, Anderson DM, Grabstein KH. Interleukin-12 regulates the proliferation of Th1, but not Th2 or Th0 clones. Eur J Immunol 1994;24: 2271-8.
12. Chouaib S, Chehimi J, Bani L, Genetet NTT, Gay F, Trinchieri G, et al. Interleukin 12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors. Proc Natl Acad Sci USA 1994;91: 12659-63.
13. Howard M, Oarra A, Ishida H, Malefyt RDW, Vries JD. Biological properties of interleukin 10. J Clin Immunol 1992;12:239-47.
14. Zheng LM, Ojcius DM Garaud F, Roth C, Maxwell E, Li Z, et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 1996;184: 579-84.
15. Chomarat P, Banchereau J. An update on interleukin-4 and its receptor. Eur Cytokine Network 1997;8:333-44.
16. Salgaller ML, Lodge PA. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J Surg Oncol 1998;68:122-38.
17. Wang J, Wei SJ, Yang WK, Lin WC, Yang DM, Whang-Peng J, et al. Immunological correlation of the effect of granulocyte-macrophage colony-stimulating factor transfer on the tumorigenicity and immunogenicity of B-16 melanoma. Int J Cancer 1996;9:1267-76.
18. Attia MA, DeOme KB, Weiss D. Immunology of spontaneous mammary carcinoma in mice. II. Resistance to rapidly and slowly developing tumor. Cancer Res 1965;25: 451-7.
19. Old LJ. Immunotherapy of cancer. Sci Am 1996;275: 136-43.
20. Dubinett SM, Miller PW, Sharma S, Batra RK. Gene therapy for lung cancer. Hematol Oncol Clin North Am 1998;12: 569-94.